Table 1 Baseline characteristics of the COVID-19-infected study cohort on hospital admission (n = 490 study participants)

Demographics

Age (years)^a

481

67 ± 18 72 [55, 81]

Gender (female: male)^a

482

42 (203): 58 (279)

BMI (kg/m²)

81

28 ± 8 25 [23, 31]

Symptoms

Cough^a

453

58 (264)

Fever (> 38,5 °C)^a

448

46 (205)

Dyspnea^a

448

57 (256)

Vital parameters

Heart rate (/min)^a

451

88 ± 19 86 [76, 100]

Systolic blood pressure (mmHg)^a

446

133 ± 22 130 [120, 145]

Respiratory rate (/min)^a

356

20 ± 6 18 [15, 22]

spO2 (%)^a

442

93,3 ± 5,8 95 [91, 97]

Laboratory findings

Lymphocytes (/nl)

294

1.73 ± 3.48 1.00 [0.66, 1.40]

Leukocytes (/nl)^a

478

7.9 ± 4.1 6.9 [5.1, 9.6]

Neutrophile granulocytes (/nl)

315

6,5 ± 10,9 4,8 [3.3, 7.3]

Creatinine (mg/dl)^a

474

1,37 ± 1,59 1.0 [0.80, 1.40]

C-reactive protein (mg/l)^a

474

84 ± 80 64 [23, 118]

Lactate dehydrogenase (U/l)^a

358

417 ± 745 322 [252, 448]

aPTT (s)^a

370

35 ± 16 32 [29, 36]

Potassium (mmol/l)^a

455

4.04 ± 0.60 3.99 [3.66, 4.36]

Procalcitonin (µg/l)

321

1.32 ± 10.37 0.09 [0.05, 0.25]

pH

369

7.43 [7.40, 7.46]

pO2 (mmHg)

361

55 ± 40 50 [28, 68]

pCO2 (mmHg)

367

39 ± 9 37 [33, 43]

sO2 (mmHg)

363

54 ± 35 56 [25, 89]

Comorbidities

Total number of comorbidities^a

445

–

No comorbidity

27 (122)

1 comorbidity

22 (100)

2 comorbidities

21 (95)

3 comorbidities

15 (67)

4 comorbidities

8.8 (39)

5 comorbidities

3.4 (15)

6 comorbidities

1.6 (7)

Type of comorbidities

Chronic kidney disease

468

18 (86)

Pulmonary disease

462

18 (82)

Diabetes mellitus

471

24 (112)

Dyslipidemia

451

14 (65)

Vascular/coronary artery disease

490

27 (131)

Hypertension

461

57 (265)

Cardiomyopathy

461

5.2 (24)

Tumor disease^a

190

19 (93)

Medication

Antiplatelet medication^a

490

27(130)

RAAS-Inhibitors^a

490

42 (204)

Antidiabetic medication^a

490

22 (106)

Immunosuppressive medication^a

490

18 (87)

Statins^a

459

21 (96)

Oral anticoagulation^a

467

14 (67)

Diuretics^a

457

24 (110)

Proton pump inhibitors^a

453

30 (135)